Arjun Agarwal Sells 9,459 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,459 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $69.72, for a total transaction of $659,481.48. Following the sale, the senior vice president owned 17,294 shares in the company, valued at $1,205,737.68. The trade was a 35.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Trading Down 1.7%

ORKA opened at $67.71 on Wednesday. The company’s 50 day moving average is $64.00 and its 200-day moving average is $44.58. Oruka Therapeutics, Inc. has a 1-year low of $10.77 and a 1-year high of $91.00. The company has a market cap of $4.08 billion, a P/E ratio of -34.90 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. On average, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its position in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the period. Royal Bank of Canada boosted its position in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics during the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. acquired a new stake in Oruka Therapeutics during the 3rd quarter worth approximately $39,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ORKA. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. BTIG Research restated a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Guggenheim set a $200.00 price target on shares of Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $131.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.